Author Archives: admin


Stem Cell Therapy Global Market Opportunities And Strategies To 2031 – Yahoo Finance

ReportLinker

provides the strategists; marketers and senior management with the critical information they need to assess the global stem cell therapy market as it emerges from the COVID 19 shut down. Description:

New York, July 11, 2022 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Stem Cell Therapy Global Market Opportunities And Strategies To 2031" - https://www.reportlinker.com/p06291564/?utm_source=GNW Where is the largest and fastest growing market for stem cell therapy? How does the market relate to the overall economy; demography and other similar markets? What forces will shape the market going forward? The stem cell therapy market global report answers all these questions and many more. The report covers market characteristics; size and growth; segmentation; regional and country breakdowns; competitive landscape; market shares; trends and strategies for this market.It traces the markets historic and forecast market growth by geography.

It places the market within the context of the wider stem cell therapy market; and compares it with other markets.

The report covers the following chapters Executive Summary The executive summary section of the report gives a brief overview and summary of the report. Report Structure This section gives the structure of the report and the information covered in the various sections. Introduction The introduction section of the report gives brief introduction about segmentation by geography, by type, by cell source, by end-user, and by application. Market Characteristics The market characteristics section of the report defines and explains the stem cell therapy market. This section also defines and describes goods and related services covered in the report. Trends And Strategies This section describes the major trends shaping the global stem cell therapy market. This section highlights likely future developments in the market and suggests approaches companies can take to exploit these opportunities. Impact of COVID-19 This section describes the impact of COVID-19 on the stem cell therapy market. Global Market Size And Growth This section contains the global historic (2016-2021) and forecast (2021-2026), and (2026-2031) market values, and drivers and restraints that support and control the growth of the market in the historic and forecast periods. Regional Analysis This section contains the historic (2016-2021) and forecast (2021-2026, and 2026-2031) market values and growth and market share comparison by region. Segmentation This section contains the market values (2016-2031) and analysis for different segments. Regional Market Size and Growth This section contains the regions market size (2021), historic (2016-2021) and forecast (2021-2026, and 2026-2031) market values, and growth and market share comparison of countries within the region.This report includes information on all the regions Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa and major countries within each region.

The market overview sections of the report describe the current size of the market, background information, government initiatives, regulations, regulatory bodies, associations, corporate tax structure, investments, and major companies. Competitive Landscape This section covers details on the competitive landscape of the global stem cell therapy market, estimated market shares and company profiles for the leading players. Key Mergers And Acquisitions This section gives the information on recent mergers and acquisitions in the market covered in the report. This section gives key financial details of mergers and acquisitions which have shaped the market in recent years. Market Opportunities And Strategies This section includes market opportunities and strategies based on findings of the research.This section also gives information on growth opportunities across countries, segments and strategies to be followed in those markets.

It gives an understanding of where there is significant business to be gained by competitors in the next five years. Conclusions And Recommendations This section includes conclusions and recommendations based on findings of the research. This section also gives recommendations for stem cell therapy providers in terms of product/service offerings, geographic expansion, marketing strategies and target groups. Appendix This section includes details on the NAICS codes covered, abbreviations and currencies codes used in this report.

Scope Markets Covered: 1) By Type: Allogeneic Stem Cell Therapy; Autologous Stem Cell Therapy 2) By Cell Source: Adult Stem Cells; Induced Pluripotent Stem Cells; Embryonic Stem Cells 3) By Application: Musculoskeletal Disorders and Wounds & Injuries; Cancer; Autoimmune Disorders; Others 4) By End-Users: Hospitals And Clinics; Research Centers; Others

Companies Mentioned: Smith & Nephew Plc; Fujifilm Holding Corporation; Thermo Fisher Scientific Inc.; Takara Bio Inc; MEDIPOST Co., Ltd.

Countries: China; Australia; India; Indonesia; Japan; South Korea; USA; Brazil; France; Germany; UK; Russia

Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa

Time series: Five years historic and ten years forecast.

Data: Ratios of market size and growth to related markets; GDP proportions; expenditure per capita; stem cell therapy indicators comparison.

Data segmentations: country and regional historic and forecast data; market share of competitors; market segments.

Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.

Reasons to Purchase Gain a truly global perspective with the most comprehensive report available on this market covering 12 geographies. Understand how the market is being affected by the coronavirus and how it is likely to emerge and grow as the impact of the virus abates. Create regional and country strategies on the basis of local data and analysis. Identify growth segments for investment. Outperform competitors using forecast data and the drivers and trends shaping the market. Understand customers based on the latest market research findings. Benchmark performance against key competitors. Utilize the relationships between key data sets for superior strategizing. Suitable for supporting your internal and external presentations with reliable high-quality data and analysis. Read the full report: https://www.reportlinker.com/p06291564/?utm_source=GNW

About Reportlinker ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

Story continues

Read the rest here:
Stem Cell Therapy Global Market Opportunities And Strategies To 2031 - Yahoo Finance

Confocal Microscope Market 2022 Analysis Trend, Applications, Growth, and Forecast to 2030 | Save 30% on this report – Taiwan News

Global Confocal Microscope Market is valued at approximately USD $million in 2021 and is anticipated to grow with a healthy growth rate of more than 4.5% over the forecast period 2022-2028.

The confocal microscope is a type of widefield fluorescence+ microscopy that produces high-resolution pictures of materials stained with fluorescent probes. Due to their tremendous benefits in image resolution, commercially made laser scanning confocal microscopes have achieved enormous popularity across the world. Because it allows photographs to be free of out-of-focus information, the method has acquired significant adoption in molecular imaging.

Download Free Sample of This Strategic Report :-https://reportocean.com/industry-verticals/sample-request?report_id=bw5794

Rising incidences of Microbial Keratitis and rising demand for Confocal Microscopy in the diagnosis of ophthalmic conditions have led to the adoption of Confocal Microscopes across the forecast period. In 2017, the Indian Department of Biotechnology published a guideline for stem cell and regenerative medicine that includes fundamental biology of all adult stem cells, early and late translational research, and the development of gene editing technologies for therapeutic applications.

Furthermore, growing number of collaborations among several prominent players to develop new and high-end products, propel the market opportunities for upcoming years. A partnership between India and Japan has been developed to assist stem cell and regenerative medicine research. Indian researchers will receive training at Kyoto Universitys Center for iPS Cell Research and Applications (CiRA). However, high price of Microscopes and lack of skilled professionals impede the growth of the market over the forecast period of 2022-2028.

The key regions considered for the global Confocal Microscope Market study include Asia Pacific, North America, Europe, Latin America, and Rest of the World. North America is leading the market share globally owing to factors such as huge investment in the research and development activities and rising prevalence of eye diseases. However, Asia Pacific is expected to be the fastest growing region due to rising demand for diagnostic centers and increasing number of healthcare facilities.

SPECIAL OFFER (Avail an Up-to 30% discount on this report :-https://reportocean.com/industry-verticals/sample-request?report_id=bw5794

Major market players included in this report are:

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming eight years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within each of the regions and countries involved in the study. Furthermore, the report also caters the detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, the report shall also incorporate available opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and Application offerings of key players. The detailed segments and sub-segment of the market are explained below:

Access full Report Description, TOC, Table of Figure, Chart, etc :-https://reportocean.com/industry-verticals/sample-request?report_id=bw5794

By Type:

Multi-Photon Microscopy

Confocal Disk Spinning

By End-user:

Hospitals

Diagnostic Laboratories

Academics & Research Institute

By Region:

North America

U.S.

Canada

Europe

UK

Germany

France

Spain

Italy

ROE

Asia Pacific

China

India

Japan

Australia

South Korea

RoAPAC

Latin America

Brazil

Mexico

Rest of the World

Access Full Report, here:-https://reportocean.com/industry-verticals/sample-request?report_id=bw5794

About Report Ocean: We are the best market research reports provider in the industry. Report Ocean believes in providing quality reports to clients to meet the top line and bottom line goals which will boost your market share in todays competitive environment. Report Ocean is a one-stop solution for individuals, organizations, and industries that are looking for innovative market research reports.

Get in Touch with Us: Report Ocean: Email:sales@reportocean.com Address: 500 N Michigan Ave, Suite 600, Chicago, Illinois 60611 UNITED STATES Tel: +1 888 212 3539 (US TOLL FREE) Website:https://www.reportocean.com/

Read more here:
Confocal Microscope Market 2022 Analysis Trend, Applications, Growth, and Forecast to 2030 | Save 30% on this report - Taiwan News

BreakPoint: Is aging a ‘disease’ and other bioethical questions for Christians – Chattanooga Times Free Press

According to the writer of Proverbs, "death and life are in the power of the tongue." So is cultural change, which most often comes with efforts to change language use and the definitions of words. For example, Harvard Medical molecular biologist David Sinclair is combining innovation in the lab with innovation in language. In a recent CNN article, one of Sinclair's financial backers described the goal of his research as changing the definition of the word "aging." He wants to "make aging a disease."

Sinclair claims to have successfully interrupted the aging process in mice by turning adult cells back into stem cells. Some animals are designed with a similar capability, albeit in a more limited way think, for example, of an octopus regrowing a leg that has been cut off. Using that same idea, what Sinclair calls an "ancient regeneration system," he hopes to regenerate cells that deteriorate with age. Already, he has been able to repair ocular cells in older mice, allowing them to recover their "youthful" eyesight.

His ultimate aim, of course, is to develop anti-aging therapies for humans. Though some concern has been directed toward the safety of Sinclair's process, what goes largely unquestioned in media coverage is Sinclair's chief aim. In other words, as so much medical ethics goes these days, if we can do it, then we should.

Medical ethics from a Christian worldview perspective is not that simple.

Whenever Christians can affirm aspects of work like David Sinclair's, which attempts to overcome the consequences of the fall, we should. The Bible teaches that death is an enemy, and that humans were not made to die. And humans should recognize that the ingenuity and passion for exploration that often inspires medical progress are God-given.

To accuse people like Sinclair of "playing God," as if that were an insult, is not helpful. After all, according to Genesis 1 and 2, human beings were created by God to, in a sense, "play God." We are not to pretend that we are God, of course, but he did gift us with the ability to work alongside him to accomplish his purposes for the world he made. After the fall, he promises to eventually restore his creation, so our work alongside him continues. The mandate to build and create, tending the garden of his world, is to be done within the moral limits that reflect his character and how he created the world.

Within this framework, causing or hastening death is a great evil, but so can be attempts to avoid death "at all costs." Jesus' own death was an act of unprecedented evil but also only fully understood in the context of his obedience to the Father's will. Jesus lay down his life, and many Christians have followed in his footsteps. Thus, there are certain moral goods such as the will of God that are higher than avoiding death.

Keeping these sorts of things straight is essential to ethically pursuing and employing technologies, like those that promise to "reverse aging." In his book "Bioethics: A Primer for Christians," bioethicist and theologian Gilbert Meilaender counsels Christians to view the freedom to pursue medical progress not as freedom from restraints, such as death. Instead, we should consider ourselves free to work alongside God imitating him on the path he set out for human flourishing. This will mean, very often in fact, not doing (as God described the men who built the tower of Babel) "whatever comes into our minds to do."

Meilaender counsels Christians to fight the temptation to use medicine not merely as a way to care for our bodies but from the desire to control them. If the chief end of medical research and practice is to live on our own terms, we will inevitably make moral compromises along the way. It was the serpent who promised Eve that she could live as she wished but evade death, which was not only a lie but not sufficient justification for attempting to usurp the authority that only belongs to God.

The goal of medical research and practice should be to help people flourish in the bodies, times, places and limits that God has given us. From this beginning, Meilaender suggests that the "principle" which should "govern Christian compassion" is not to "minimize suffering," but to "maximize care."

Our purpose is not to avoid suffering or even death at all costs despite that they are effects of the fall we are called to oppose. Rather, we take into account that in God's mercy, even our suffering can be redeemed for good. We lament the hard realities of our fallen world, and we seek to understand them within the larger context of creation and resurrection. Thus, we know that death is not the end of life, nor is life only a prerequisite to death.

From BreakPoint, July 8, 2022; reprinted by permission of the Colson Center, breakpoint.org.

Visit link:
BreakPoint: Is aging a 'disease' and other bioethical questions for Christians - Chattanooga Times Free Press

Global Induced Pluripotent Stem Cell (iPSC) Market Report 2022: Rising Applications of iPSCs Fueling Industry Growth – ResearchAndMarkets.com -…

DUBLIN--(BUSINESS WIRE)--The "Global Induced Pluripotent Stem Cell (iPSC) Industry Report, 2022" report has been added to ResearchAndMarkets.com's offering.

Since the discovery of induced pluripotent stem cell (iPSC) technology in 2006, significant progress has been made in stem cell biology and regenerative medicine. New pathological mechanisms have been identified and explained, new drugs identified by iPSC screens are in the pipeline, and the first clinical trials employing human iPSC-derived cell types have been initiated.

iPSCs can be used to explore the causes of disease onset and progression, create and test new drugs and therapies, and treat previously incurable diseases.

Other applications of iPSCs include their use as research products, as well as their integration into 3D bioprinting, tissue engineering, and clean meat production. Technology allowing for the mass-production and differentiation of iPSCs in industrial-scale bioreactors is also advancing at breakneck speed.

iPSC Derived Clinical Trials

The first clinical trial using iPSCs started in 2008, and today, that number has surged worldwide. Most of the current clinical trials do not involve the transplant of iPSCs into humans, but rather, the creation and evaluation of iPSC lines for clinical purposes. Within these trials, iPSC lines are created from specific patient populations to determine if these cell lines could be a good model for a disease of interest.

The therapeutic applications of induced pluripotent stem cells (iPSCs) have also surged in recent years. Since the discovery of iPSCs in 2006, it took only seven years for the first iPSC-derived cell product to be transplanted into a human patient in 2013. Since then, iPSC-derived cells have been used within a rapidly growing number of preclinical studies, physician-led studies, and formal clinical trials worldwide.

Key Topics Covered:

1. Report Overview

2. Introduction

3. Current Status of iPSC Industry

3.1 Progress Made in Autologous Cell Therapy Using iPSCs

3.2 Manufacturing Timeline for Autologous iPSC-Derived Cell Products

3.3 Cost of iPSC Production

3.4 Automation in iPSC Production

3.5 Allogeneic iPSCs Gaining Momentum

3.6 Share of iPSC-Based Research Within the Overall Stem Cell Industry

3.7 Major Focus Areas of iPSC Companies

3.8 Commercially Available iPSC-Derived Cell Types

3.9 Relative Use of iPSC-Derived Cell Types in Toxicology Testing Assays

3.10 Currently Available iPSC Technologies

4. History of Induced Pluripotent Stem Cells (iPSCs)

5. Research Publications on iPSCs

6. iPSC: Patent Landscape Analysis

6.1 Legal Status of iPSC Patents

6.2 Patents by Assignee Organization Type

6.3 Ownership of Patent Families by Assignee Type

6.4 Top Inventors of iPSC Patents

6.5 Top Ten iPSC Inventors

6.6 Most Cited Five iPSC Patents

6.7 Leading Patent Filing Jurisdictions

6.8 Number of Patent Families by Year of Filing

6.9 Patents Representing Different Disorders

6.10 iPSC Patents on Preparation Technologies

6.11 Patents on Cell Types Differentiated from iPSCs

6.12 Patent Application Trends Disease-Specific Technologies

7. iPSC: Clinical Trial Landscape

7.1 Literature and Database Search

7.2 Number of iPSC Clinical Trials by Year

7.3 iPSC Study Designs

7.4 iPSC-Based Clinical Trials With Commercialization Potential

8. Research Funding for iPSCs

8.1 Value of NIH Funding for iPSC Research

8.2 Partial List of NIH Funded iPSC Research Projects in 2022

9. M&A, Collaborations & Funding Activities in iPSC Sector

10. Generation of Induced Pluripotent Stem Cells: An Overview

10.1 Reprogramming Factors

10.2 Integrating iPSC Delivery Methods

10.3 Non-Integrative Delivery Systems

10.4 Comparison of Delivery Methods for Generating iPSCs

10.5 Genome Editing Technologies in iPSC Generation

11. Human iPSC Banking

11.1 Cell Sources for iPSC Banking

11.2 Reprogramming Methods Used in iPSC Banking

11.3 Factors Used in Reprogramming in Different Banks

11.4 Workflow in iPSC Banks

11.5 Existing iPSC Banks

12. Biomedical Applications of iPSCs

12.1 iPSCs in Basic Research

12.2 iPSCs in Drug Discovery

12.3 iPSCs in Toxicology Studies

12.4 iPSCs in Disease Modeling

12.5 iPSCs in Cell-Based Therapies

12.6 Other Novel Applications of iPSCs

12.7 iPSCs in Animal Conservation

13. Market Overview

Companies Mentioned

For more information about this report visit https://www.researchandmarkets.com/r/mg6l5h

Go here to read the rest:
Global Induced Pluripotent Stem Cell (iPSC) Market Report 2022: Rising Applications of iPSCs Fueling Industry Growth - ResearchAndMarkets.com -...

Gut bacteria nurture the immune system for cancer patients, a diverse microbiome can protect against dangerous treatment complications – The…

One promising treatment for patients with blood cancers is stem cell transplantation. Doctors completely eliminate the patients immune system by aiming chemotherapy, radiation or both at their bone marrow before replacing it with a donors immune system. Because the bone marrow produces blood and immune cells, completely substituting cancerous bone marrow with healthy cells could help the body reestablish a functioning immune system and replace cancerous blood cells.

This procedure is not without risks. A key complication hematologists like me worry about is graft-versus-host disease, where the donors immune system recognizes the patients body as foreign and launches an attack. Up to 50% of patients who receive a stem cell transplant develop graft-versus-host disease.

One unexpected part of the body that may play a key role in protecting transplant patients from complications, however, is their gut bacteria.

Alongside my colleagues Hana Andrlova and Marcel van den Brink, I study how the composition of your microbiome, or the microorganisms living in your body, can affect how well cancer treatments work. While previous studies have shown that disruptions to the diversity of organisms in the gut microbiome is linked to a higher risk of death after transplantation, the precise reasons for this are not clear.

In our recently published study, we found that gut bacteria help the immune system recover from stem cell transplants by nurturing two special types of immune cells that protect against complications.

To explore the relationship between gut bacteria and the immune system, we first needed to identify the types of bacteria present in a given microbiome. So we sequenced all the bacterial genes in the stool samples of 174 stem cell transplant patients. We then took blood samples from the same patients to identify which types of immune cells were circulating and how they were functioning.

We learned that a diverse intestinal microbiome after transplantation is associated with expansion of a particular type of cell called MAIT, or mucosal-associated invariant T cells. MAIT cells are linked to improved transplant outcomes like a lower risk of graft-versus-host disease and longer survival in both mice and people. We found that the more MAIT cells patients had in their blood after transplant, the longer they survived and the fewer their complications. Patients with the highest levels of MAIT cells had the lowest incidence of graft-versus-host disease.

The precise mechanism behind the protective effects of MAIT cells is unclear. But researchers do know that these cells require molecules that come from the process of producing riboflavin, or vitamin B2, in the body to develop and multiply. Turns out, these riboflavin derivatives are produced by the microbes in the gut.

We also found that high MAIT cell numbers were linked to the presence of another special population of T cells, V-delta-2, that are also stimulated by bacterial byproducts. Above-average levels of these cells were also associated with better survival and less graft-versus-host disease in transplant patients.

These findings suggest that one of the reasons why a healthy, diverse microbiome is linked to good results for stem cell transplant recipients could be that gut bacteria support the development of immune cells that protect against transplant complications like graft-versus-host disease.

Our next step was to figure out how these special T cells protect against transplant complications. We took blood samples from five patients who had high numbers of MAIT and V-delta-2 cells. We then used a technique called single-cell RNA sequencing to analyze thousands of individual cells and explore all the potential functions any particular cell type may have in the body.

When we compared the MAIT and V-delta-2 cells of transplant patients and healthy people, our findings were very surprising. We had originally hypothesized that genes linked with tissue repair would be active in these T cells that would explain why patients with high numbers of these cells do better after such intense treatment thats so tough on the body. Instead, we found that these cells had highly expressed genes involved in inflammatory processes with the capacity to induce cell damage sometimes necessary to fight off infections when the patients immune system is still recovering. This suggests that MAIT and V-delta-2 cells may be protecting patients from transplant complications in ways that we havent previously been aware of or understood.

Its possible that T cells that are activated by the microbiome like MAIT and V-delta-2 help reduce transplant complications by killing infected cells or cells involved in graft-versus-host disease. While we arent able to confirm this hypothesis with our study, future work may help scientists better understand the important links between the microbiome, the immune system and successful stem cell transplants for cancer patients.

Here is the original post:
Gut bacteria nurture the immune system for cancer patients, a diverse microbiome can protect against dangerous treatment complications - The...

Krabbe disease, which mostly affects newborns causes, symptoms, and treatment – CNBCTV18

Krabbe disease is one of many hundreds of inherited metabolic disorders. Named after the Danish neurologist Knud Krabbe, the disease causes progressive damage to the nervous system, eventually resulting in the death of the individual. The disease is common in newborns before they reach six months of age and treatment must start at the earliest. Most newborns affected by Krabbe disease do not reach the age of two.

Krabbe disease is caused due to genetic mutation on the 14th chromosome in an infant. A child needs to inherit two copies of the abnormal genome from both its parents, after which it has a 25 percent chance of inheriting both the recessive genes and developing the disease.

On inheriting the defective genome, the body doesnt produce enough of the enzyme galactosylceramidase (GALC). Galactosylceramidase is essential for breaking down unmetabolised lipids like glycosphingolipid and psychosine in the brain. These unmetabolised lipids are toxic to some of the non-neuron cells present in the brain.

Late-onset Krabbe disease, however, can be caused by a different genetic mutation which leads to a lack of a different enzyme, known as active saposin A.

Symptoms between early-onset and late-onset Krabbe disease differ slightly. Infants suffering from early-onset Krabbe disease suffer from symptoms like excessive irritability, difficulty swallowing, vomiting, unexplained fevers, and partial unconsciousness. Other common neuropathic symptoms include hypersensitivity to sound, muscle weakness, slowing of mental and motor development, spasticity, deafness, optic atrophy, optic nerve enlargement, blindness, and paralysis.

Late-onset Krabbe disease emerges with symptoms like the development of cross-eyes, slurred speech, slow development, and loss of motor functions.

The disease is diagnosed after a physician conducts a primary physical exam. A blood or skin tissue biopsy can test for GALC levels in the body and low levels can indicate the presence of Krabbe disease. Further testing through imaging scans (MRI), nerve conduction studies, eye examination, genetic testing and amniocentesis can also help diagnose the disease.

There is no cure for Krabbe disease. Treatment is mostly palliative in nature with a focus towards dealing with symptoms and providing supportive care. Experimental trials using hematopoietic stem cell transplant (HSCT), bone marrow transplantation, stem cell therapy, and gene therapy have seen some results in the small number of patients that they have been used on.

(Edited by : Shoma Bhattacharjee)

First Published:Jul 15, 2022, 06:32 AM IST

Original post:
Krabbe disease, which mostly affects newborns causes, symptoms, and treatment - CNBCTV18

Ola Landgren, MD, PhD, Highlights How DETERMINATION Trial Results Inform Use of RVd/Transplant in Newly Diagnosed Myeloma – Cancer Network

C. Ola Landgren, MD, PhD, a professor and leader of Experimental Therapeutics and Myeloma Service at the Sylvester Comprehensive Cancer Center, University of Miami Health System, in an interview with CancerNetwork highlighted key efficacy findings from the phase 3 DETERMINATION trial (NCT01208662) assessing the use of lenalidomide (Revlimid), bortezomib (Velcade), and dexamethasone (RVd) plus autologous stem cell transplant vs RVd alone, both with continuous lenalidomide maintenance, in patients with newly diagnosed multiple myeloma.1 Moreover, he highlights how the findings compare with similar research such as the phase 3 IFM/DFCI2009 trial (NCT01191060) which previously assessed RVd alone or with high-dose transplant followed by 1 year of lenalidomide maintenance in newly diagnosed multiple myeloma.2

Patients treated on DETERMINATION who received RVd alone had a median progression-free survival (PFS) of 46.2 months compared with 67.5 months in the transplant group (HR, 1.53; 95% CI, 1.23-1.91; P <.0001). The rates of partial response or better were 95.0% and 97.5% in each respective group. No overall survival benefit was noted in either arm (HR, 1.10; 95% CI, 0.73-1.65; P = .99).

Transcript:

The DETERMINATION study showed very similar [findings to the phase 3 IFM/DFCI2009 trial in] that there is a progression-free survival benefit following bone marrow transplant; it was found to be around 21 months. Thats a quite long time. But also, they showed that there is no survival difference [between the 2 treatment arms]. The follow-up time is only around 5 years in the DETERMINATION trial, which is slightly shorter [than IFM/DFCI2009] but confirms very similar results.

Another very important difference between the 2 studies was that in the DETERMINATION study, of the patients on the non-transplant arm [who progressed], a much lower proportion of those patients went to transplant [vs IFM/DFCI2009]. In the DETERMINATION study, it was in the range of 20% to 25% while in the IFM/DFCI2009 study it was 70% to 80%. Despite the fact that there were fewer patients who went to transplant at the time of relapse in the non-transplant up-front arm, you still see no survival difference. Of course, this raises the question [as to whether] you need to do a transplant upfront, do you need to delay it, or do you never need to do the transplant?

This is exactly what Joseph Mikhael, MD, [of the Translational Genomics Research Institute], talked about as the discussant at ASCO. He made a very good, balanced, and fair evaluation when he said that you can make a case for transplant. If you want to extend PFS, you can make a case against the transplant not showing survival difference. There were a lot of other nuances, [such as] the onset of second malignancies. There were 10 cases of [acute myeloid leukemia and myelodysplastic syndrome] in the transplant arm and none in the non-transplant arm. There were quality-of-life differences in favor of no transplant; patients had several months of worsening as expected of their quality of life [following] transplant. Mikhael summarize saying, Welcome to the future of myelomathe era of choice. It is no longer mandatory for patients to do transplant. And I agree with that.

See the article here:
Ola Landgren, MD, PhD, Highlights How DETERMINATION Trial Results Inform Use of RVd/Transplant in Newly Diagnosed Myeloma - Cancer Network

New cancer treatment changing outlook for those with blood cancers – WBAL TV Baltimore

Ten percent of all diagnosed cancers in the United States are blood cancers and they can be deadly. There are exciting new treatments and research happening in Baltimore that are giving patients hope."These therapies cure the patients that have no other treatment options. It's been a remarkable breakthrough," Dr. Aaron Rapoport, of the University of Maryland School of Medicine, said.Cutting-edge technology in cancer treatment will treat many types of cancers such as leukemia, lymphoma, and myeloma. Traditional treatments include chemotherapy, radiation, and stem cell therapy, but what if those treatments don't work? Now there is an immunotherapy for aggressive blood cancers that is seeing remarkable results.Chip Baldwin has a big laugh and immense love for his grandchildren."This is Kyle, he's about 3 1/2 years old and he lives in Florida. (My) granddaughter Maple. She and her family live in Fells Point. And this is (my) granddaughter Rosemary and she's a doll, and they call me Pop-pop," Baldwin said.Baldwin almost never met two of his grandchildren. In January 2018, he was told chemotherapy was no longer working to treat his lymphoma. He thought it was the end."Leaving (my wife) Angela and leaving the family, trying to figure out how they're going to get by," Baldwin said. He was out of options, or so he thought. Not willing to give up, his wife, Angela Baldwin, began researching and came across a promising new treatment."Probably the last treatment that I could have received. Had I not received it and had it not been positive to put me in remission, I probably wouldn't be talking to you today," Baldwin said.The treatment he received had just been approved by the U.S. Food and Drug Administration (FDA) months earlier. It's called "CAR T-cell Therapy." It uses the patient's own, re-engineered, immune cells to kill cancer. Rapoport helped pioneer the development of CAR T-cell at the University of Maryland Greenebaum Comprehensive Cancer Center. Baldwin was just the second patient here to receive it."The notion that one could perhaps harness the immune system, or educate the immune system, to better protect us from cancer, but also to recognize and fight against cancer, has been a goal for decades - centuries really," Rapoport said.It appears that goal has been reached. Here's how it works: The medical team extracts immune cells, called T-cells, out of the patient's blood. The cells are sent to a special lab in California, where scientists change the cells' DNA to put receptors on them called "CAR" - Chimeric Antigen Receptors. They enable the immune cells to recognize, hunt down and kill the cancer cells. The California lab then sends the now-re-engineered immune cells back to the Greenebaum Comprehensive Cancer Center."These are CAR T-cells growing in the flask here. These are CAR T-cells that were made in the lab," Dr. Djordje Atanackovic of the University of Maryland Medical Center, said. Under a microscope you can see spots on a cancer cell - those spots are the killer CAR T-cells. "You could use these right now to treat a patient, actually," Atanackovic said.For the final step, patients are admitted to the hospital and the medical team puts the T-cells back into the patient, where they multiply by the millions and destroy the cancer. For Baldwin, that was the day after Easter 2018."And, then about four months later, they determined that all the cancer cells had died, " Baldwin said."Being told that their scans are negative is a really overwhelming experience, not just for the patients, but for the families and also the nurses and physicians. The team members that are involved in their care," Rapoport said.When looking at CT scan images of two other lymphoma patients, you see black areas in the images on one is extensive cancer. The other image shows the same patient after CAR T-cell therapy and the cancer is gone. Right now, CAR T-cell Therapy is approved to treat aggressive blood cancers Lymphoma, B-cell Leukemia and Myeloma. But Atanackovic believes that's just the beginning."I'm pretty optimistic that in 10 years from now we'll have novel immunotherapies that we can't even imagine at this point for everyone, or at least most of our patients with cancer," Atanackovic said.Four years after his treatment and Baldwin is still in remission. He doesn't like the word "cure" because he's afraid it's bad luck. The word he keeps coming back to is: "Unbelievable. And even to this day, I kind of can't believe I'm in remission and I'm able to live my life. Since then, I've had two grandchildren and it's been wonderful. Had it not been for the University and the treatment, I would never have seen the two kids," Baldwin saidSo far, 250 patients have been treated with CAR T-cell Therapy at the University of Maryland, but it's not perfect and researchers are still working to improve it. The success rate for patients with aggressive lymphoma for example is 50% and some patients have side effects like flu-like symptoms, so they typically stay in the hospital for days or even weeks.Many may be wondering is this covered by insurance? The answer is yes. Keep in mind, right now it is approved by FDA as a second-line therapy, so you do have to try a different treatment first. But, immunotherapy like CAR-T is the future of cancer treatment and you're going to see more of it.

Ten percent of all diagnosed cancers in the United States are blood cancers and they can be deadly. There are exciting new treatments and research happening in Baltimore that are giving patients hope.

"These therapies cure the patients that have no other treatment options. It's been a remarkable breakthrough," Dr. Aaron Rapoport, of the University of Maryland School of Medicine, said.

Cutting-edge technology in cancer treatment will treat many types of cancers such as leukemia, lymphoma, and myeloma. Traditional treatments include chemotherapy, radiation, and stem cell therapy, but what if those treatments don't work? Now there is an immunotherapy for aggressive blood cancers that is seeing remarkable results.

Chip Baldwin has a big laugh and immense love for his grandchildren.

"This is Kyle, he's about 3 1/2 years old and he lives in Florida. (My) granddaughter Maple. She and her family live in Fells Point. And this is (my) granddaughter Rosemary and she's a doll, and they call me Pop-pop," Baldwin said.

Baldwin almost never met two of his grandchildren. In January 2018, he was told chemotherapy was no longer working to treat his lymphoma. He thought it was the end.

"Leaving (my wife) Angela and leaving the family, trying to figure out how they're going to get by," Baldwin said.

He was out of options, or so he thought. Not willing to give up, his wife, Angela Baldwin, began researching and came across a promising new treatment.

"Probably the last treatment that I could have received. Had I not received it and had it not been positive to put me in remission, I probably wouldn't be talking to you today," Baldwin said.

The treatment he received had just been approved by the U.S. Food and Drug Administration (FDA) months earlier. It's called "CAR T-cell Therapy." It uses the patient's own, re-engineered, immune cells to kill cancer.

Rapoport helped pioneer the development of CAR T-cell at the University of Maryland Greenebaum Comprehensive Cancer Center. Baldwin was just the second patient here to receive it.

"The notion that one could perhaps harness the immune system, or educate the immune system, to better protect us from cancer, but also to recognize and fight against cancer, has been a goal for decades - centuries really," Rapoport said.

It appears that goal has been reached. Here's how it works:

The medical team extracts immune cells, called T-cells, out of the patient's blood. The cells are sent to a special lab in California, where scientists change the cells' DNA to put receptors on them called "CAR" - Chimeric Antigen Receptors. They enable the immune cells to recognize, hunt down and kill the cancer cells. The California lab then sends the now-re-engineered immune cells back to the Greenebaum Comprehensive Cancer Center.

"These are CAR T-cells growing in the flask here. These are CAR T-cells that were made in the lab," Dr. Djordje Atanackovic of the University of Maryland Medical Center, said.

Under a microscope you can see spots on a cancer cell - those spots are the killer CAR T-cells.

"You could use these right now to treat a patient, actually," Atanackovic said.

For the final step, patients are admitted to the hospital and the medical team puts the T-cells back into the patient, where they multiply by the millions and destroy the cancer. For Baldwin, that was the day after Easter 2018.

"And, then about four months later, they determined that all the cancer cells had died, " Baldwin said.

"Being told that their scans are negative is a really overwhelming experience, not just for the patients, but for the families and also the nurses and physicians. The team members that are involved in their care," Rapoport said.

When looking at CT scan images of two other lymphoma patients, you see black areas in the images on one is extensive cancer. The other image shows the same patient after CAR T-cell therapy and the cancer is gone.

Right now, CAR T-cell Therapy is approved to treat aggressive blood cancers Lymphoma, B-cell Leukemia and Myeloma. But Atanackovic believes that's just the beginning.

"I'm pretty optimistic that in 10 years from now we'll have novel immunotherapies that we can't even imagine at this point for everyone, or at least most of our patients with cancer," Atanackovic said.

Four years after his treatment and Baldwin is still in remission. He doesn't like the word "cure" because he's afraid it's bad luck.

The word he keeps coming back to is: "Unbelievable. And even to this day, I kind of can't believe I'm in remission and I'm able to live my life. Since then, I've had two grandchildren and it's been wonderful. Had it not been for the University and the treatment, I would never have seen the two kids," Baldwin said

So far, 250 patients have been treated with CAR T-cell Therapy at the University of Maryland, but it's not perfect and researchers are still working to improve it.

The success rate for patients with aggressive lymphoma for example is 50% and some patients have side effects like flu-like symptoms, so they typically stay in the hospital for days or even weeks.

Many may be wondering is this covered by insurance? The answer is yes. Keep in mind, right now it is approved by FDA as a second-line therapy, so you do have to try a different treatment first. But, immunotherapy like CAR-T is the future of cancer treatment and you're going to see more of it.

Excerpt from:
New cancer treatment changing outlook for those with blood cancers - WBAL TV Baltimore

CAR T-Cell Therapy Appeared Safe, With No Signs of GVHD in Patients With T-Cell Lymphoma/Leukemia – DocWire News

A study presented at the 2022 American Society of Clinical Oncology Annual Meeting found that an autologous CD7 chimeric antigen receptor (CAR) T-cell therapy was effective for patients with relapsed/refractory T-cell acute lymphoblastic leukemia and lymphoma (ALL/LBL), with no signs of graft-versus-host disease (GVHD) reported.

The phase I study included patients with CD7+ relapsed/refractory T-cell ALL/LBL with no leukemic cells in the peripheral blood. Following a 3+3 dose escalation process, the CD7 CAR construct included an endoplasmic reticulum anchor domain fused to a CD7 binding domain to prevent CD7 expression on cell surface, which contributed to minimizing CAR T-cell fratricide. CAR T product was checked to ensure lack of tumor contamination before infusion.

Between September 2021 and January 2022, 5 patients (median age, 3.8 years; range, 1.9-13.0 years) were enrolled in the study. Of those patients, 1 had mediastinal mass and blasts in pleural fluid, 1 had central nervous system-3 status, and 3 had marrow disease with a median burden of 1.35% (range, 0.07%-7.31%).

Patients received CAR T-cell therapy at the following doses: 5 105 cells/kg (n = 3) and 1 106 cells/kg (n = 1). One patient received cells below the target dose.

A total of 3 patients had cytokine release syndrome (CRS), and 1 patient experienced grade 3 CRS. Median onset to CRS was 5 days (range, 1-9 days), with a median duration of 4 days (range, 3-14 days). There were no reports of neurotoxicity, GVHD, or infection.

All patients experienced grade 3/4 hematologic toxicities, which recovered to grade 2 within 30 days.

At 1 month post-infusion, 4 patients achieved complete remission, and 1 patient still had leukemia cells in the cerebrospinal fluid. At a median follow-up of 62 days (range, 35-136 days), 1 patient underwent hematopoietic stem cell transplantation (HSCT) at 2.9 months post-infusion and had a CD7 relapse at 1.4 months post-HSCT. The other 3 patients who experienced a response were in minimal residual disease-negative complete remission.

In the 4 patients who received target dose, the median peak CAR T-cell count in peripheral blood was 4.27 102/L (range, 2.49-5.61) by flow cytometry. All patients had detectable CAR transgene by polymerase chain reaction at their last visits.

Longer follow-up with more patients is needed to further evaluate this CAR T-cell therapy, the researchers noted.

Zhao L, Pan J, Tang K, et al. Autologous CD7-targeted CAR T-cell therapy for refractory or relapsed T-cell acute lymphoblastic leukemia/lymphoma. Abstract #7035. Presented at the 2022 American Society of Clinical Oncology Annual Meeting; June 3-7, 2022; Chicago, IL.

Continue reading here:
CAR T-Cell Therapy Appeared Safe, With No Signs of GVHD in Patients With T-Cell Lymphoma/Leukemia - DocWire News

Innovative Therapies, Care Equity Highlight 2022 ASCO Annual Meeting – Targeted Oncology

After a meeting like the 2022 ASCO Annual Meeting, one cannot help but be reinvigorated to continue advancing cancer care and feel optimistic about the future of oncology, says John M. Burke, MD.

After seeing all the amazing presentations at the American Society of Oncology (ASCO) Annual Meeting, I cannot help but reflect on how far our field has come over the course of my 20-year career.

In 2000, I moved from San Francisco, California, to New York, New York, to begin my fellowship at Memorial Sloan Kettering Cancer Center. My first rotation was on the inpatient myeloma, lymphoma, and autologous stem cell transplant service, where I encountered patients with myeloma and painful bone lesions causing fractures and spinal cord compressions. We treated patients with myeloma with chemotherapy and autologous stem cell transplant. Thalidomide (Thalomid) was starting to make a splash by showing strong efficacy in myeloma trials, and bortezomib (Velcade) emerged during those years, as well.

Nevertheless, the state of the art was exemplified by an article in the New England Journal of Medicine in 2003, describing the results of an Intergroupe Francophone du Mylome (IFM) trial. Myeloma patients were treated with vincristine, doxorubicin, and dexamethasone induction followed by single or double autologous stem cell transplant. The median event-free survival was 2 years and the median overall survival was 4 years, which seem grim by modern standards.

Fast forward about 20 years to the Plenary Session of the 2022 ASCO Annual Meeting, at which we saw the results of modern therapy in the DETERMINATION trial (NCT01208662). Patients treated with the modern standard regimen of lenalidomide (Revlimid), bortezomib, and dexamethasone followed by autologous stem cell transplant achieved a median progression-free survival of 5.5 years. In the IFM trial 20 years ago, approximately 50% of patients were alive at 4 years. In DETERMINATION, 85% of patients were alive at 4 years. Weve come a long way.

DETERMINATION represents only an infinitesimal fraction of the degree of innovation demonstrated at the ASCO meeting: an antibody-drug conjugate besting conventional chemotherapy in patients with low expression of the HER2 target in breast cancer; a KRAS inhibitor demonstrating marked activity in KRAS-mutated nonsmall cell lung cancer; a bispecific antibody redirecting T cells to suppress diffuse large B-cell lymphoma; an antibody-drug conjugate added to chemotherapy, extending survival in Hodgkin lymphoma compared with the decades-old standard-of-care regimen; and a checkpoint inhibitor rendering mismatch repairdeficient rectal cancer completely helpless.

After a meeting like this, one cannot help but be reinvigorated to continue advancing cancer care and feel optimistic about the future of oncology. We have a lot of progress to celebrateand a lot more to accomplish.

Read the original post:
Innovative Therapies, Care Equity Highlight 2022 ASCO Annual Meeting - Targeted Oncology